Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

11 August 2014
roche-location-big

The Scottish Medicines Consortium has approved the prescribing on the National Health Service of Swiss drug major Roche’s (SIX: ROG) subcutaneous RoActemra (tocilizumab) for use in Scotland in the treatment of rheumatoid arthritis.

The company sees this approval as particularly important for those in Scotland who live in rural and remote locations, far from hospitals, since subcutaneous RoActemra can be administered at hospital or home, unlike its intravenous formulation.

It is the first anti interleukin (IL)-6 receptor inhibitor for use with and without methotrexate, which provides a new option for patients who cannot or will not continue with methotrexate, which causes incomplete responses and/or adverse events in 20%-40% of patients. RoActemra/Actemra generated sales of 568 million Swiss francs ($628 million) in the first half of 2014.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical